Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Acquired by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company lifted its position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) by 22.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,919 shares of the biotechnology company’s stock after buying an additional 2,361 shares during the period. The Manufacturers Life Insurance Company’s holdings in Capricor Therapeutics were worth $178,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in CAPR. Vanguard Group Inc. increased its holdings in shares of Capricor Therapeutics by 44.4% during the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock worth $31,420,000 after buying an additional 700,243 shares during the last quarter. Altium Capital Management LLC increased its holdings in shares of Capricor Therapeutics by 150.5% during the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock worth $9,853,000 after buying an additional 429,000 shares during the last quarter. Black Diamond Financial LLC acquired a new stake in shares of Capricor Therapeutics during the 4th quarter worth $3,833,000. Geode Capital Management LLC increased its holdings in shares of Capricor Therapeutics by 37.8% during the 4th quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock worth $12,139,000 after buying an additional 241,279 shares during the last quarter. Finally, Kennedy Capital Management LLC acquired a new stake in shares of Capricor Therapeutics during the 4th quarter worth $1,991,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Trading Down 1.3%

Shares of Capricor Therapeutics stock opened at $9.44 on Monday. The company has a fifty day moving average price of $10.70 and a 200 day moving average price of $13.67. Capricor Therapeutics Inc has a twelve month low of $3.52 and a twelve month high of $23.40. The stock has a market cap of $431.19 million, a price-to-earnings ratio of -8.91 and a beta of 0.85.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.20). Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The business had revenue of $2.73 million for the quarter, compared to analysts’ expectations of $3.16 million. During the same period last year, the company posted ($0.31) earnings per share. Analysts forecast that Capricor Therapeutics Inc will post -1.21 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently commented on CAPR shares. Cantor Fitzgerald restated an “overweight” rating and set a $30.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, May 14th. HC Wainwright restated a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Monday, March 17th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $36.40.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.